Concepedia

Calvin Jia

CJ

Statistics

Publications

5

Citations

91

H-Index

5

Active since

2021

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Fox Chase Cancer Center

Carolina Urologic Research Center

Erasmus MC Cancer Institute

University of Washington

Calvin Jia is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and metastatic urothelial carcinoma immunotherapy.

Publications per year

2021–2024

5

Publications

5

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

Matt D. Galsky, Andrea Necchi, Neal D. Shore et al. · Journal of Clinical Oncology · 2021 · 23 citations

, , +12

Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Andrea Necchi, Jens Bedke, Matt D. Galsky et al. · Journal of Clinical Oncology · 2023 · 22 citations

, , +12

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

Yohann Loriot, Petros Grivas, Ronald de Wit et al. · Journal of Clinical Oncology · 2022 · 19 citations · Full text

, , +15

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

İrfan Çiçin, Elizabeth R. Plimack, Howard Gurney et al. · BMC Cancer · 2024 · 14 citations · Full text

, , +17

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi, Michiel S. van der Heijden, Dmytro Trukhin et al. · BMC Cancer · 2024 · 13 citations · Full text

, , +14

1–5 of 5